This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Rao, V. S. Articles by Bonavida, B. Search for Related Content PubMed PubMed Citation Articles by Rao, V. S. Articles by Bonavida, B.

Detection of Soluble Tumor-associated Antigens in Serum of Tumor-bearing Rats and Their Immunological Role in Vivo¹

Department of Microbiology and Immunology, School of Medicine, The Center for the Health Sciences, University of California at Los Angeles, Los Angeles, California 90024

Circulating soluble tumor antigens were detected in the serum of tumor-bearing rats. Sublethally irradiated W/Fu rats inoculated with syngeneic C58(NT)D Gross virus-induced lymphoma served as the source of tumor antigens. Soluble antigens were assessed by specific inhibition of the complement-mediated cytotoxicity of isogenic W/Fu anti-C58(NT)D antibodies against ⁵¹Cr tumor target cells. With a s.c. inoculum of 5 x 10⁷ tumor cells, circulating tumor antigens were first detected at Day 8, and a maximum concentration was reached by Day 13 to 14, which coincided with the peak of tumor growth and was followed by the sudden death of the animals. Pooled serum from tumorbearing rats was fractionated on Sephadex G-150 and resulted in one peak that contained all of the antigenic activity. The molecular weight of this fraction was estimated to be 50,000 to 60,000 daltons. Presensitization of normal rats with soluble tumor antigens resulted in a specific acceleration of tumor growth and delay in tumor rejection. Specificity was shown by lack of C58(NT)D tumor enhancement in rats presensitized with serum containing tumor antigens from a syngeneic but antigenically unrelated WR-6 lymphoma. The biological significance of circulating soluble tumor antigen mediating specific immunosuppression against an immunogenic tumor is discussed.

¹ Supported by Grant CA 12800 from the National Cancer Institute, NIH, Bethesda, Md. Part of this work was presented at the 67th Annual Meeting of the American Association for Cancer Research (20).

² Present address: Department of Pharmacology and Medicine, Yale University School of Medicine, New Haven, Conn. 06510.

³ To whom requests for reprints should be addressed.

Received 3/ 4/77. Accepted 6/ 1/77.